Amgen Inc
NASDAQ:AMGN
Intrinsic Value
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. [ Read More ]
The intrinsic value of one AMGN stock under the Base Case scenario is 252.58 USD. Compared to the current market price of 262.75 USD, Amgen Inc is Overvalued by 4%.
Valuation Backtest
Amgen Inc
Run backtest to discover the historical profit from buying and selling AMGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Amgen Inc
Current Assets | 30.3B |
Cash & Short-Term Investments | 10.9B |
Receivables | 7.3B |
Other Current Assets | 12.1B |
Non-Current Assets | 66.8B |
PP&E | 5.9B |
Intangibles | 51.3B |
Other Non-Current Assets | 9.6B |
Current Liabilities | 18.4B |
Accounts Payable | 18.5B |
Accrued Liabilities | 15.4B |
Other Current Liabilities | -15.5B |
Non-Current Liabilities | 72.5B |
Long-Term Debt | 63.2B |
Other Non-Current Liabilities | 9.4B |
Earnings Waterfall
Amgen Inc
Revenue
|
28.2B
USD
|
Cost of Revenue
|
-8.4B
USD
|
Gross Profit
|
19.8B
USD
|
Operating Expenses
|
-11.6B
USD
|
Operating Income
|
8.2B
USD
|
Other Expenses
|
-1.4B
USD
|
Net Income
|
6.7B
USD
|
Free Cash Flow Analysis
Amgen Inc
What is Free Cash Flow?
AMGN Profitability Score
Profitability Due Diligence
Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
AMGN Solvency Score
Solvency Due Diligence
Amgen Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Score
Amgen Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMGN Price Targets Summary
Amgen Inc
According to Wall Street analysts, the average 1-year price target for AMGN is 313.65 USD with a low forecast of 171.7 USD and a high forecast of 399 USD.
Ownership
AMGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AMGN Price
Amgen Inc
Average Annual Return | 14.6% |
Standard Deviation of Annual Returns | 18.85% |
Max Drawdown | -19% |
Market Capitalization | 140.7B USD |
Shares Outstanding | 535 919 008 |
Percentage of Shares Shorted | 1.96% |
AMGN News
Last Important Events
Amgen Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Amgen Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
Contact
IPO
Employees
Officers
The intrinsic value of one AMGN stock under the Base Case scenario is 252.58 USD.
Compared to the current market price of 262.75 USD, Amgen Inc is Overvalued by 4%.